Shimla Online

PCSK9 Inhibitors Market Size was approximately USD 1,309 Million in 2021 | DelveInsight

 Breaking News
  • No posts were found

PCSK9 Inhibitors Market Size was approximately USD 1,309 Million in 2021 | DelveInsight

November 29
17:20 2022
PCSK9 Inhibitors Market Size was approximately USD 1,309 Million in 2021 | DelveInsight

The PCSK9 Inhibitors market dynamics are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world and rising cases of statin resistance in patients with Familial Hypercholesterolemia as well as increasing risk of cardiovascular conditions such as myocardial infarction, coronary revascularization etc. Key players, such as LIB Therapeutics, Ionis Pharmaceuticals, AstraZeneca, CiVi Biopharma, and others are currently developing PCSK9 Inhibitors drugs. DelveInsight’s PCSK9 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, PCSK9 Inhibitors emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

 

Key Takeaways from the PCSK9 Inhibitors Market Research Report

  • According to DelveInsight estimates the PCSK9 Inhibitors market size in the 7MM was found to be approximately USD 1.1 billion in 2021.
  • As per the analysis, the total number of PCSK9 Inhibitors prevalent cases in the 7MM was approximately 3.1 million in 2021.
  • PCSK9 Inhibitors companies LIB Therapeutics, AstraZeneca, CiVi Biopharma, Sanofi, Regeneron Pharmaceuticals, Amgen, Novartis, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Akeso Biopharma, Innovent Biologics, and others.
  • The PCSK9 Inhibitors therapies in the pipeline include LIB003, AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVi-008, and others.

 

To read more about the latest drug development related to PCSK9 Inhibitors, get a snapshot of the key highlights included in the PCSK9 Inhibitors Market Size Report

 

PCSK9 Inhibitors Overview

PCSK9 inhibitors, in combination with other LDL lowering drugs, have been demonstrated to be highly effective for some people. Studies have shown that these drugs reduce LDL-C by 40–65% beyond the effect of other lipid-lowering drugs. The use of a PCSK9 inhibitor can reduce the chance of heart attack and stroke. New PCSK9 inhibitors are in development and are currently in clinical trials. The development of PCSK9 inhibitors, which are monoclonal antibodies directed against PCSK9, led to a significant enhancement of the lipid-lowering armamentarium, as PCSK9 inhibitors result in a consistent and robust reduction in LDL-C serum concentrations, substantially improving CV outcomes.

 

PCSK9 Inhibitors Epidemiology Segmentation in the 7MM

  • Total PCSK9 inhibitors Prevalent Cases
  • Total PCSK9 inhibitors Diagnosed Cases
  • PCSK9 inhibitors Type-specific Cases
  • PCSK9 inhibitors Age group-specific Cases
  • PCSK9 inhibitors Mutation-specific Cases
  • PCSK9 inhibitors Risk factor-specific Cases
  • Total PCSK9 inhibitors Treated Cases

 

To know more about the PCSK9 inhibitors drugs market growth, get a snapshot of the report PCSK9 inhibitors Market Analysis Report

 

PCSK9 Inhibitors Market Insights

Monoclonal antibodies directed at PCSK9 are the first to be approved. There are currently two FDA approved PCSK9 inhibitors namely, alirocumab and evolocumab available in the United States for adult patients to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease as an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of adults with primary hyperlipidemia (including HeFH) to reduce LDL-cholesterol. Evolocumab is also approved as an adjuvant to diet and other LDL-reducing treatments in individuals with HoFH who require further LDL-C reduction. The mAb PCSK9 inhibitors evolocumab and alirocumab reduce LDL-C levels by roughly 60% when combined with statin treatment and reduce the risk of severe vascular events. Both of these PCSK9 Inhibitors drugs have the same PCSK9 Inhibitors mechanism of action. In addition, large PCSK9 Inhibitors trials have demonstrated that PCSK9 inhibitors, when added to the statin-based treatment, cut ASCVD risk even more, and their usage may need to be restricted to individuals at greatest risk for ASCVD.

 

PCSK9 Inhibitors Market Dynamics

The PCSK9 Inhibitors market dynamics is expected to change in the coming years due to several factors such as the improvement in the rise in the number of healthcare spending globally and rising cases of statin resistance in patients with familial hypercholesterolemic as well increasing risk of cardiovascular conditions such as myocardial infarction, coronary revascularization etc. Furthermore, the PCSK9 inhibition in a prophylactic setting can relieve the CVD burden and thus impacting the PCSK9 Inhibitors market positively. In addition, the implications of PCSK9 inhibitors in broader therapy areas also contribute towards the growth of the PCSK9 Inhibitors market. Though monoclonal antibodies have, for the time being, established themselves as the most clinically useful inhibitors of PCSK9, other novel therapies are currently in various stages of development and will be available soon in the PCSK9 Inhibitors market.

 

PCSK9 Inhibitors Market Growth

However, certain factors are limiting the growth of the PCSK9 Inhibitors market. To date, little information is available on the real impact of PCSK9 inhibitors in terms of reducing cholesterolemia, events, and the actual tolerability. This lack of information is substantially majorly related to the fact that these drugs have only been marketed recently and thus impacting the PCSK9 Inhibitors market growth. Moreover, despite manufacturers working for years on generating evidence, there are still reimbursement restrictions for the two PCSK9 agents in large European PSCK9 Inhibitors markets such as France, the UK, Italy, Germany, and Spain. In addition, the commercial payer actions affect PCSK9 Inhibitors market access and sales of Repatha. Furthermore, the use of off-label therapies and generics are also among the factors that are hindering the PCSK9 Inhibitors market growth.

 

PCSK9 Inhibitors Pipeline Therapies and Key Companies

  • LIB003 (Lerodalcibep): LIB Therapeutics
  • AZD8233 (ION449): AstraZeneca and Ionis Pharmaceuticals
  • Cepadacursen sodium (CIVI-007): CiVi Biopharma
  • CiVI-008: CiVi Biopharma

 

Get a sneak peek at the PCSK9 Inhibitors Market Dynamics @ PCSK9 Inhibitors Treatment Market

 

 

Scope of the PCSK9 Inhibitors Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • PCSK9 Inhibitors Companies- LIB Therapeutics, AstraZeneca, CiVi Biopharma, Sanofi, Regeneron Pharmaceuticals, Amgen, Novartis, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Akeso Biopharma, Innovent Biologics, and others.
  • PCSK9 Inhibitors therapies in the pipeline include LIB003, AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVi-008, and others
  • PCSK9 Inhibitors Market Drivers, Barriers, Access, Unmet Needs, KOL Views

 

Table of content

1. Key Insights

2. PCSK9 Inhibitors Executive Summary

3. Competitive Intelligence Analysis for PCSK9 Inhibitors

4. PCSK9 Inhibitors: Market Overview at a Glance

5. PCSK9 Inhibitors: Disease Background and Overview

7. PCSK9 Inhibitors Epidemiology and Patient Population

8. PCSK9 Inhibitors Treatment Algorithm, Current Treatment, and Medical Practices

9. PCSK9 Inhibitors Unmet Needs

10. Key Endpoints of PCSK9 Inhibitors Treatment

11. PCSK9 Inhibitors Marketed Products

12. PCSK9 Inhibitors Emerging Therapies

13. PCSK9 Inhibitors: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: PCSK9 Inhibitors Market Outlook

16. Access and Reimbursement Overview of PCSK9 Inhibitors

17. KOL Views

18. PCSK9 Inhibitors Market Drivers

19. PCSK9 Inhibitors Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Discover more about the future market share of PCSK9 Inhibitors treatment therapies @ PCSK9 Inhibitors Market Barriers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles